Advertisement

Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies

      Objective

      To assess the pharmacokinetics and pharmacodynamics of levonorgestrel intrauterine system (LNG-IUS) 13.5 mg and LNG-IUS 19.5 mg (total content).

      Design

      Pooled pharmacokinetic and pharmacodynamic analyses of phase II and III studies.

      Setting

      Randomized, open-label, multicenter studies.

      Patient(s)

      Nulliparous and parous women.

      Intervention(s)

      Levonorgestrel intrauterine system 13.5 mg, LNG-IUS 19.5 mg, or LNG-IUS 20 μg/24 h (total content 52 mg).

      Main Outcome Measure(s)

      Pharmacokinetics of LNG, ovulation rate, cervical function, and endometrium effects.

      Result(s)

      The in vivo LNG release rate of LNG-IUS 13.5 mg was approximately 14 μg/24 h after 24 days, declining progressively to 5 μg/24 h after 3 years. The average LNG serum concentration over 3 years of use was 74.3 ng/L, 114 ng/L, and 218 ng/L for LNG-IUS 13.5 mg, LNG-IUS 19.5 mg, and LNG-IUS 20 μg/24 h, respectively. All treatments showed very similar progestogenic effects on cervical mucus, with low and similar cervical scores throughout treatment. Ovulation was observed in the majority of women in all groups where assessment was possible, although there was a lower incidence of anovulation with LNG-IUS 13.5 mg and LNG-IUS 19.5 mg compared with LNG-IUS 20 μg/24 h. The progestogenic effect on the endometrium was marked in all three LNG-IUS groups.

      Conclusion(s)

      Levonorgestrel intrauterine system 13.5 mg and LNG-IUS 19.5 mg result in alower systemic exposure to LNG, lower incidence of anovulation, and similar progestin impact on the endometrium and cervical function compared with LNG-IUS 20 μg/24 h.

      Key Words

      To read this article in full you will need to make a payment

      References

      1. Bayer HealthCare Pharmaceuticals Inc. Mirena prescribing information. 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed March 25, 2013.

        • Nilsson C.G.
        • Lahteenmaki P.L.
        • Luukkainen T.
        Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device.
        Fertil Steril. 1984; 41: 52-55
      2. Scholten PC. Thesis. The Levonorgestrel IUD: clinical performance and impact on menstruation. Utrecht: University Hospital, 1989.

        • Xiao B.L.
        • Zhou L.Y.
        • Zhang X.L.
        • Jia M.C.
        • Luukkainen T.
        • Allonen H.
        Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.
        Contraception. 1990; 41: 353-362
      3. Population Council. Jadelle (levonorgestrel implant) prescribing information. 2002. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20544se2-003_jadelle_lbl.pdf. Accessed February 8, 2013.

      4. Bayer. Norgeston summary of product characteristics. 2012. Available at: http://www.medicines.org.uk/emc/medicine/1834. Accessed April 18, 2013.

      5. Berlex Laboratories. Levlite physician label. 2001. Available at: http://www.berlex.com/html/products/pi/levlite_pi.pdf. Accessed April 18, 2013.

        • Andersson K.
        • Odlind V.
        • Rybo G.
        Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.
        Contraception. 1994; 49: 56-72
        • Gemzell-Danielsson K.
        • Schellschmidt I.
        • Apter D.
        A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
        Fertil Steril. 2012; 97: 616-622
        • Nelson A.L.
        • Apter D.
        • Hauck B.
        • Schmelter T.
        • Rybowski S.
        • Rosen K.
        • et al.
        Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
        Obstet Gynecol. 2013; 122: 1205-1213
      6. Bayer Group. Mirena product information. 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed October 18, 2013.

        • Israel R.
        • Mishell Jr., D.R.
        • Stone S.C.
        • Thorneycroft I.H.
        • Moyer D.L.
        Single luteal phase serum progesterone assay as an indicator of ovulation.
        Am J Obstet Gynecol. 1972; 112: 1043-1046
        • Shepard M.K.
        • Senturia Y.D.
        Comparison of serum progesterone and endometrial biopsy for confirmation of ovulation and evaluation of luteal function.
        Fertil Steril. 1977; 28: 541-548
        • Insler V.
        • Melmed H.
        • Eichenbrenner I.
        • Serr D.M.
        • Lunenfeld B.
        The cervical score. A simple semiquantitative method for monitoring of the menstrual cycle.
        Int J Gynaecol Obstet. 1972; 10: 223-228
      7. Bayer Pharma AG. Mirena product monograph. Berlin, Germany: Bayer Pharma AG, 2012.

        • Endrikat J.
        • Blode H.
        • Gerlinger C.
        • Rosenbaum P.
        • Kuhnz W.
        A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
        Eur J Contracept Reprod Health Care. 2002; 7: 79-90
        • Fotherby K.
        Levonorgestrel. Clinical pharmacokinetics.
        Clin Pharmacokinet. 1995; 28: 203-215
        • Bahamondes M.V.
        • Monteiro I.
        • Castro S.
        • Espejo-Arce X.
        • Bahamondes L.
        Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
        Hum Reprod. 2010; 25: 1158-1164
        • Barbosa I.
        • Bakos O.
        • Olsson S.E.
        • Odlind V.
        • Johansson E.D.
        Ovarian function during use of a levonorgestrel-releasing IUD.
        Contraception. 1990; 42: 51-66
        • Jonsson B.
        • Landgren B.M.
        • Eneroth P.
        Effects of various IUDs on the composition of cervical mucus.
        Contraception. 1991; 43: 447-458
        • Lewis R.A.
        • Taylor D.
        • Natavio M.F.
        • Melamed A.
        • Felix J.
        • Mishell Jr., D.
        Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability.
        Contraception. 2010; 82: 491-496
        • Critchley H.O.
        • Wang H.
        • Kelly R.W.
        • Gebbie A.E.
        • Glasier A.F.
        Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
        Hum Reprod. 1998; 13: 1210-1217
        • Zhu P.
        • Liu X.
        • Luo H.
        • Gu Z.
        • Cheng J.
        • Xu R.
        • et al.
        The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use.
        Hum Reprod. 1999; 14: 970-975
        • Silverberg S.G.
        • Haukkamaa M.
        • Arko H.
        • Nilsson C.G.
        • Luukkainen T.
        Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices.
        Int J Gynecol Pathol. 1986; 5: 235-241